Research & Development

TripleMed is developing a breakthrough minimally-invasive approach to treating aortic aneurysms – both abdominal (AAA’s) and thoracic (TAA’s). The TripleMed technique is known as NSAR – pronounced “ensar” – for Non-Surgical Aneurysm Repair. It has the potential to treat all patients with an aneurysm, including the roughly 50% of treated patients world-wide who currently undergo traditional open surgery. The other 50% of treated patients receive endovascular stent grafts – a market which is forecast to reach US$1 billion in 2012. The TripleMed NSAR approach is designed to be applicable to all of these patients and remove the risk of endoleaks (blood entering the aneurysm in spite of the stent graft). As a totally percutaneous (using only a needle and no scalpel) procedure, NSAR joins the trend of moving therapeutic procedures from the operating theatre into the radiology suite.

An aortic aneurysm is a bulging or ballooning of the wall of the aorta (the main artery leading from the heart). More than 90% of aneurysms occur in the abdomen below the level of the arteries leading to the kidneys and they are most common in men over 60 years old. AAA’s are generally asymptomatic and therefore detected as a result of a routine examination or during an evaluation for an alternative condition. However, as the results of a rupture of the aneurysm are very serious, the potential for worthwhile screening programmes exist and these are now being implemented, for example for Medicare eligible patients in the USA since 2007 and the NHS AAA Screening Programme in the UK which is currently being rolled out. The number of aneurysms detected before rupture is therefore growing and with the advances in endovascular repair techniques, the number receiving stent grafts is also increasing year on year.

For further information on Aortic Aneurysms, please see the following links:

Triplemed illustration